Cytokinetics | Muscle Biology Therapies

Now Available | Primary Results of GALACTIC-HF Published in NEJM

Read the primary results from GALACTIC-HF, the Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure, published in the New England Journal of Medicine.

cardiovascular disease

Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.

NEUROMUSCULAR DISEASE

Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.

Press Releases

February 26, 2021Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 26, 2021Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
February 25, 2021Cytokinetics Reports Fourth Quarter 2020 Financial Results

view all

Cytokinetics Corporate Presentation

Download

Pipeline

We have robust pipeline of small molecule muscle activators and inhibitors, including omecamtiv mecarbil, reldesemtiv, CK-274, CK-136 and CK-601.

Careers

We seek exceptional individuals to join us in our mission to develop the next generation of novel small molecule muscle-directed potential medicines.